FDA Com. Young on OTCs
Rx-to-OTC switches will be one of FDA's priority issues Young said in a Nov. 12 letter to the World Federation of Proprietary Medicine Mfrs. general assembly in Tokyo. Noting that in addition to "tackling" the OTC Review, FDA has nearly finished the DESI program, the letter, read by former FDA Com. Alexander Schmidt, MD, said: "We have not been idle, and you should know that I will engage my staff in equally demanding activities as we move on to other priorities. One of these must involve the switching of Rx drugs to OTC status"
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.